The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 29, 2013

Filed:

Jun. 22, 2010
Applicants:

Yehoshua Shachar, Santa Monica, CA (US);

Winston Wu, Alhambra, CA (US);

Thomas Chen, La Canada, CA (US);

Brett Jordan, Los Angeles, CA (US);

Kyle Zimmerman, Los Angeles, CA (US);

Herwin Chan, Los Angeles, CA (US);

Paladin Luboff, Santa Monica, CA (US);

Inventors:

Yehoshua Shachar, Santa Monica, CA (US);

Winston Wu, Alhambra, CA (US);

Thomas Chen, La Canada, CA (US);

Brett Jordan, Los Angeles, CA (US);

Kyle Zimmerman, Los Angeles, CA (US);

Herwin Chan, Los Angeles, CA (US);

Paladin Luboff, Santa Monica, CA (US);

Assignee:

Pharmaco-Kinesis Corporation, Century City, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/48 (2006.01);
U.S. Cl.
CPC ...
G01N 33/48 (2013.01);
Abstract

A biosensor for detection of vascular endothelial growth factor (VEGF) hybridization uses an array of parallel capacitors to detect electrochemical binding of circulating VEGF to immobilized anti-VEGF monoclonal half-antibodies (a-VEGF mhAb). Binding of a-VEGF mhAb modulates the threshold voltage of a circuit, changing the impedance of the circuit. An electrode coated with a p-Si substrate enhances the affinity between the VEGF molecules. A fluid cell delivers VEGF samples onto the active surface of the chip. An array of parallel capacitors arranged in an interdigitated pattern detects the VEGF in the fluid. The detector provides an accurately measured and quantifiable rate of change of the VEGF molecules in vivo, providing real time feedback which is used to measure response of the tumor to delivered chemotherapeutic agents and biological response modifiers (BRMs) for the purpose of determining tumor burden and efficacy of the chemotherapy as part of a homeostatic loop for chemotherapy.


Find Patent Forward Citations

Loading…